Management of Refractory Ascites Due to Portal Hypertension: Current Status.

Refractory ascites is a costly and debilitating condition that occurs most frequently in the setting of substantial cirrhotic portal hypertension, where it portends a poor prognosis. Many treatment options are available, among them medical management, serial large volume paracenteses, transjugular intrahepatic portosystemic shunts, and implanted drainage devices. Although the availability of multiple therapies ensures that most patients will achieve satisfactory results, it can be challenging for the provider to select the appropriate treatment for each specific patient. This article reviews the available therapeutic options for refractory ascites and incorporates available data and clinical experience to suggest a linear stepwise management approach to enhance patient outcomes.

• Publication year

  2021

• Venue

  Radiology

• Publication date

  2021-01-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1148/radiol.2021201960PMID 33497318
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Relative Sarcopenia With Excess Adiposity Predicts Survival After Transjugular Intrahepatic Portosystemic Shunt Creation.

  2019cited by this paper
• The modification of quantity and quality of muscle mass improves the cognitive impairment after TIPS

  2019cited by this paper
• Muscle Gain after Transjugular Intrahepatic Portosystemic Shunt Creation: Time Course and Prognostic Implications for Survival in Cirrhosis.

  2019cited by this paper
• The Journal of Hospital Medicine in 2019 and Beyond.

  2019cited by this paper
• Current and future pharmacological therapies for managing cirrhosis and its complications

  2019cited by this paper
• Automated low-flow ascites pump in a real-world setting: complications and outcomes

  2018cited by this paper
• Cost-Effectiveness of Transjugular Intrahepatic Portosystemic Shunt versus Large-Volume Paracentesis in Refractory Ascites: Results of a Markov Model Incorporating Individual Patient-Level Meta-Analysis and Nationally Representative Cost Data.

  2018cited by this paper
• Hospital volume and mortality after transjugular intrahepatic portosystemic shunt creation in the United States

  2018cited by this paper
• Patients with refractory ascites treated with alfapump® system have better health-related quality of life as compared to those treated with large volume paracentesis: the results of a multicenter randomized controlled study

  2018cited by this paper
• Transjugular Intrahepatic Portosystemic Shunt Using the New Gore Viatorr Controlled Expansion Endoprosthesis: Prospective, Single-Center, Preliminary Experience

  2018cited by this paper
• The influence of a peritoneovenous shunt for cirrhotic and malignant intractable ascites on renal function

  2018cited by this paper
• Cost Effectiveness of Early Insertion of Transjugular Intrahepatic Portosystemic Shunts for Recurrent Ascites

  2018cited by this paper
• EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis.

  2018cited by this paper
• Symptomatic Fluid Drainage: Tunneled Peritoneal and Pleural Catheters

  2017cited by this paper
• Home-based drainage of refractory ascites by a permanent-tunneled peritoneal catheter can safely replace large-volume paracentesis.

  2017cited by this paper
• Effects of alfapump™ system on kidney and circulatory function in patients with cirrhosis and refractory ascites

  2017cited by this paper
• Safety and Effectiveness of Palliative Tunneled Peritoneal Drainage Catheters in the Management of Refractory Malignant and Non-malignant Ascites

  2017cited by this paper
• Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites.

  2017cited by this paper
• Transjugular Intrahepatic Portosystemic Shunts in Patients with Cirrhosis with Refractory Ascites: Comparison of Clinical Outcomes by Using 8- and 10-mm PTFE-covered Stents.

  2017cited by this paper
• Symptomatic Fluid Drainage: Peritoneovenous Shunt Placement

  2017cited by this paper
• Treatment of refractory ascites with an automated low‐flow ascites pump in patients with cirrhosis

  2017cited by this paper
• Alfapump® system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study.

  2017cited by this paper
• Automated low-flow ascites pump for the treatment of cirrhotic patients with refractory ascites

  2017cited by this paper
• Ascites, refractory ascites and hyponatremia in cirrhosis

  2017cited by this paper
• The Transjugular Intrahepatic Portosystemic Shunt: Technique and Instruments.

  2016cited by this paper
• Treatment of Patients with Cirrhosis.

  2016cited by this paper
• The Impact of Tunneled Catheters for Ascites and Peritoneal Carcinomatosis on Patient Rehospitalizations

  2016cited by this paper
• Tenckhoff tunneled peritoneal catheter placement in the palliative treatment of malignant ascites: technical results and overall clinical outcome

  2016cited by this paper
• Management of refractory ascites in cirrhosis: Are we out of date?

  2016cited by this paper
• Rates of and Reasons for Hospital Readmissions in Patients With Cirrhosis: A Multistate Population-based Cohort Study.

  2016cited by this paper
• Therapeutic Application of Percutaneous Peritoneovenous (Denver) Shunt in Treating Chylous Ascites in Cancer Patients.

  2016cited by this paper
• Indwelling Peritoneal Catheters for Managing Malignancy-Associated Ascites

  2015cited by this paper
• Automated low flow pump system for the treatment of refractory ascites: a single-center experience

  2015cited by this paper
• Do vasopressin V2 receptor antagonists benefit cirrhotics with refractory ascites?

  2015cited by this paper
• Repeat Large-Volume Paracentesis Versus Tunneled Peritoneal Catheter Placement for Malignant Ascites: A Cost-Minimization Study.

  2015cited by this paper
• Management of symptomatic ascites and post-operative lymphocysts with an easy-to-use, patient-controlled, vascular catheter.

  2015cited by this paper
• Paracentesis-Induced Circulatory Dysfunction: A Primer for the Interventional Radiologist

  2014cited by this paper
• Adherence to a moderate sodium restriction diet in outpatients with cirrhosis and ascites: a real‐life cross‐sectional study

  2014cited by this paper
• TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis.

  2014cited by this paper
• Safety and Efficacy of the PleurX Catheter for the Treatment of Malignant Ascites

  2014cited by this paper
• Covered vs. uncovered stents for transjugular intrahepatic portosystemic shunt: a randomized controlled trial.

  2014cited by this paper
• Safety and Efficacy of Fibrinolytic Therapy in Restoring Function of an Obstructed Tunneled Pleural Catheter.

  2014cited by this paper
• Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012

  2013cited by this paper
• Hypervolemic hyponatremia: Clinical significance and management

  2013cited by this paper
• Tunneled peritoneal drainage catheter placement for refractory ascites: single-center experience in 188 patients.

  2013cited by this paper
• Automated low flow pump system for the treatment of refractory ascites: a multi-center safety and efficacy study.

  2013cited by this paper
• Hospital Readmissions Among Patients With Decompensated Cirrhosis

  2012cited by this paper
• Albumin infusion in patients undergoing large‐volume paracentesis: A meta‐analysis of randomized trials

  2012cited by this paper
• Safety, cost-effectiveness and feasibility of daycase paracentesis in the management of malignant ascites with a focus on ovarian cancer

  2012cited by this paper
• Percutaneous placement and management of the Denver shunt for portal hypertensive ascites.

  2012cited by this paper
• Technical and clinical outcome of transjugular intrahepatic portosystemic stent shunt: bare metal stents (BMS) versus viatorr stent-grafts (VSG).

  2012cited by this paper
• Muscle wasting is associated with mortality in patients with cirrhosis.

  2012cited by this paper
• Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone

  2012cited by this paper
• Radiological Insertion of Denver Peritoneovenous Shunts for Malignant Refractory Ascites: A Retrospective Multicenter Study (JIVROSG-0809)

  2011cited by this paper
• Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis

  2010cited by this paper
• Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial

  2010cited by this paper
• Clinical efficacy of transjugular intrahepatic portosystemic shunt created with covered stents with different diameters: results of a randomized controlled trial.

  2010cited by this paper
• Peritoneal and Pleural Ports for Management of Refractory Ascites and Pleural Effusions: Assessment of Impact on Patient Quality of Life and Hospice/Home Nursing Care

  2009cited by this paper
• Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial

  2009cited by this paper
• Risk of complications after abdominal paracentesis in cirrhotic patients: a prospective study.

  2009cited by this paper
• Peritoneal catheter for continuous drainage of ascites in advanced cancer patients

  2008cited by this paper
• Prospective evaluation of the PleurX catheter when used to treat recurrent ascites associated with malignancy.

  2008cited by this paper
• Efficacy and safety of the stepped care medical treatment of ascites in liver cirrhosis: a randomized controlled clinical trial comparing two diets with different sodium content.

  2008cited by this paper
• Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long‐term results of a randomized multicentre study

  2007cited by this paper
• Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data.

  2007cited by this paper
• Radiological Insertion and Management of Peritoneovenous Shunt

  2007cited by this paper
• Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies.

  2006cited by this paper
• Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid:

  2006cited by this paper
• A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites.

  2005cited by this paper
• Transjugular intrahepatic portosystemic shunt in refractory ascites: a meta‐analysis

  2005cited by this paper
• Peritoneovenous Shunt as a Bridge to Liver Transplantation

  2005cited by this paper
• Should bleeding tendency deter abdominal paracentesis?

  2005cited by this paper
• Severe haemorrhage following abdominal paracentesis for ascites in patients with liver disease

  2005cited by this paper
• Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis.

  2005cited by this paper
• Quality of life in refractory ascites: Transjugular intrahepatic portal‐systemic shunting versus medical therapy

  2005cited by this paper
• Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study.

  2004cited by this paper
• Correlation between portal/hepatic vein gradient and response to transjugular intrahepatic portosystemic shunt creation in refractory ascites.

  2004cited by this paper
• Management of cirrhosis and ascites.

  2004cited by this paper
• Survival after elective transjugular intrahepatic portosystemic shunt creation: prediction with model for end-stage liver disease score.

  2004cited by this paper
• Comparison of percutaneous management techniques for recurrent malignant ascites.

  2004cited by this paper
• The management of ascites in cirrhosis: Report on the consensus conference of the international Ascites club

  2003cited by this paper
• Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis.

  2003cited by this paper
• The North American Study for the Treatment of Refractory Ascites.

  2003cited by this paper
• Palliative Treatment of Malignant Refractory Ascites by Positioning of Denver Peritoneovenous Shunt

  2002cited by this paper
• Improved Quality of Life in Patients with Refractory or Recidivant Ascites after Insertion of Transjugular Intrahepatic Portosystemic Shunts

  2002cited by this paper
• Tunneled peritoneal catheter placement under sonographic and fluoroscopic guidance in the palliative treatment of malignant ascites.

  2001cited by this paper
• A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites.

  2000cited by this paper
• A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts

  2000cited by this paper
• Effect of transjugular intrahepatic portosystemic shunt on quality of life.

  1996cited by this paper
• Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club.

  1996cited by this paper
• Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. French Group of Clinicians and a Group of Biologists.

  1996cited by this paper
• Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis.

  1996cited by this paper
• Care of patients with ascites.

  1994cited by this paper
• Is sinusoidal portal hypertension a necessary factor for the development of hepatic ascites?

  1992cited by this paper
• The Serum-Ascites Albumin Gradient Is Superior to the Exudate-Transudate Concept in the Differential Diagnosis of Ascites

  1992cited by this paper
• Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (2)

  1988cited by this paper
• Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis

  1988cited by this paper
• Coagulopathy Post Peritoneovenous Shunt

  1987cited by this paper
• Portal hypertension: a permissive factor only in the development of ascites and variceal bleeding.

  1986cited by this paper
• Complications of Denver peritoneovenous shunting.

  1982cited by this paper

• Management of Ascites: AJR Expert Panel Narrative Review.

  2025cites this paper
• Proximal splenic artery embolization for treatment of refractory ascites, a single‐center experience

  2024cites this paper
• Recent developments in the management of ascites in cirrhosis

  2024cites this paper
• Budd-Chiari-like syndrome in a dog secondary to a gunshot wound treated with balloon angioplasty and endovascular stent placement.

  2023cites this paper
• A soft, bioinspired artificial lymphatic system for interactive ascites transfer

  2023cites this paper
• LVP vs TIPS for Refractory Ascites: Where Do We Stand?

  2022cites this paper
• Endovascular lymphatic decompression by thoracic duct stenting for refractory ascites in cirrhotic patients: pilot study.

  2022cites this paper
• Imaging-guided interventions modulating portal venous flow: Evidence and controversies

  2022cites this paper
• Successful management of refractory ascites in non-TIPSable patients using percutaneous thoracic duct stenting.

  2021cites this paper
• New-onset autoimmune hepatitis following mRNA COVID-19 vaccination in a 36-year-old woman with primary sclerosing cholangitis – should we be more vigilant?

  2021cites this paper
• World Journal of Gastrointestinal Pathophysiology

  year unknowncites this paper